Personalized Medicine Based on Theranostic Radioiodine Molecular Imaging for Differentiated Thyroid Cancer

Ahn, Byeong‐Cheol

doi:10.1155/2016/1680464

Cited by 53 publications

(42 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…325,326 Major strides have been made in understanding the underlying biology of cancer and improving methods for designing and synthesising targeted theranostic drugs. For example, metaiodobenzylguanidine has been used for many years for diagnostic imaging and treatment of neuroblastoma, paraganglioma, and phaeochromocytoma.…”

Section: Nuclear Medicine and Imagingmentioning

confidence: 99%

Future cancer research priorities in the USA: a Lancet Oncology Commission

Jaffee

Dang

Agus

et al. 2017

The Lancet Oncology

176

123

View full text Add to dashboard Cite

We are in the midst of a technological revolution that is providing new insights into human biology and cancer. In this era of big data, we are amassing large amounts of information that is transforming how we approach cancer treatment and prevention. Enactment of the Cancer Moonshot within the 21st Century Cures Act in the USA arrived at a propitious moment in the advancement of knowledge, providing nearly US$2 billion of funding for cancer research and precision medicine. In 2016, the Blue Ribbon Panel (BRP) set out a roadmap of recommendations designed to exploit new advances in cancer diagnosis, prevention, and treatment. Those recommendations provided a high-level view of how to accelerate the conversion of new scientific discoveries into effective treatments and prevention for cancer. The US National Cancer Institute is already implementing some of those recommendations. As experts in the priority areas identified by the BRP, we bolster those recommendations to implement this important scientific roadmap. In this Commission, we examine the BRP recommendations in greater detail and expand the discussion to include additional priority areas, including surgical oncology, radiation oncology, imaging, health systems and health disparities, regulation and financing, population science, and oncopolicy. We prioritise areas of research in the USA that we believe would accelerate efforts to benefit patients with cancer. Finally, we hope the recommendations in this report will facilitate new international collaborations to further enhance global efforts in cancer control.

show abstract

Section: Nuclear Medicine and Imagingmentioning

confidence: 99%

Future cancer research priorities in the USA: a Lancet Oncology Commission

Jaffee

Dang

Agus

et al. 2017

The Lancet Oncology

176

123

View full text Add to dashboard Cite

show abstract

“…Benedict Cassen performed the first radioiodine imaging of thyroid gland in 1950 at University of California, Los Angeles (UCLA) (16). The uptake of radioiodine in the thyroid tissue is based on iodine transport via the expression of NIS ( Human epidermal growth factor receptor 2 212 Pb-TCMC-trastuzumab for imaging and therapy; other radiometals such as 89 Zr, 64 Cu have also been used…”

Section: Review: Radiotheranostics In Cancer Diagnosis and Managementmentioning

confidence: 99%

Radiotheranostics in Cancer Diagnosis and Management

Jadvar¹,

Chen²,

Cai³

et al. 2018

Radiology

101

View full text Add to dashboard Cite

The fundamental foundation for precision medicine is accurate and specific targeting of cancer cells. Advances in the understanding of cancer biology, developments in diagnostic technologies, and expansion of therapeutic options have all contributed to the concept of personalized cancer care. Theranostics is the systematic integration of targeted diagnostics and therapeutics. The theranostic platform includes an imaging component that "sees" the lesions followed by administration of the companion therapy agent that "treats" the same lesions. This strategy leads to enhanced therapy efficacy, manageable adverse events, improved patient outcome, and lower overall costs. Radiotheranostics refers to the use of radionuclides for the paired imaging and therapy agents. Radioiodine is the classic radiotheranostic agent that has been used clinically in management of thyroid diseases for nearly 75 years. More recently there have been major exciting strides in radiotheranostics for neuroendocrine tumors and prostate cancer, among other conditions. Regulatory approval of a number of radiotheranostic pairs is anticipated in the near future. Continued support will be needed in research and development to keep pace with the current momentum in radiotheranostics innovations. Moreover, regulatory and reimbursement agencies need to streamline their requirements for seamless transfer of the radiotheranostic agents from the bench to the bedside. In this review, the concept, history, recent developments, current challenges, and outlook for radiotheranostics in the treatment of patients with cancer will be discussed. RSNA, 2018.

show abstract

“…Although the term of theranostics was generated after the second millennium, radionuclide theranostics has been successfully employed for oncologic diseases since radioiodine was first used to treat thyroid cancer more than 75 years ago [2][3][4]. In the era of precision medicine, detecting molecular therapeutic targets in cancers is a major prerequisite for developing the optimal therapeutic strategy for individual patients.…”

mentioning

confidence: 99%

“…The radionuclide theranostics, which started in the thyroidologic arena by using free radioiodine, is developing to various oncologic fields by applying sophisticated nuclear, chemical, biologic, and other technologies [4]. In the territory of radionuclide theranostics, if you are able to see lesions, in general, you can treat the lesions.…”

mentioning

confidence: 99%